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(Pernyataan Survivin dalam Sel-sel Eksfoliatif Pangkal Rahim sebagai Ujian 
Diagnostik daripada Proses-proses Malignan Pangkal Rahim)
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ABSTRACT
Papanicolaou test is a diagnostic test for uterine cervical cancer screening and routinely examined. It has limitations. 
A better technique is needed to identify true cervical malignancy process. Molecular cancer marker detection may have 
high the sensitivity and specificity in detecting cancer. Survivin, a marker candidate, is upregulated in many malignancy 
processes. Ninety women have joined in this cross sectional study by consecutive sampling. Survivin expression was 
examined by indirect immunoperoxidase method. It was predominantly found in metaplastic cells. Correlation between 
survivin expression and Papanicolaou test results was calculated by Fischer’s-exact test. Using Papanicolaou test result 
as an indicator for the presence of uterine cervical abnormalities, the performance indicators were calculated. Fischer’s-
exact test showed that survivin expression was not significantly useful as cervical cancer molecular marker. Survivin 
expression of the uterine cervical exfoliative cells cannot be used as a diagnostic test for uterine cervical malignancy 
process.
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ABSTRAK
Ujian Papanicolau adalah sebuah ujian diagnostik bagi pemeriksaan barah pangkal rahim (kanser serviks) dan dilakukan 
secara rutin. Ujian ini mempunyai beberapa had. Suatu teknik yang lebih baik diperlukan bagi mengenal pasti proses 
malignansi serviks yang sebenarnya. Survivin, satu calon penanda kanser, meningkat kadarnya dalam banyak proses 
malignansi. Sembilan puluh wanita telah menyertai kajian keratan lintang ini melalui pensampelan berturutan. Pernyataan 
survivin diperiksa dengan menggunakan kaedah imunoperoksidas tidak langsung. Korelasi antara ekspresi survivin dengan 
keputusan ujian Pap dikira dengan menggunakan ujian Fischer’s-exact. Seterusnya, dengan menggunakan keputusan 
yang diperoleh daripada ujian Papanicolau sebagai penunjuk adanya keganjilan serviks, penunjuk prestasi daripada 
immunositokimia daripada survivin boleh dikira. Ujian Fischer’s-exact menunjukkan bahawa ekspresi survivin tidak 
berguna secara penuh makna sebagai penanda kanser serviks secara molekular. Pernyataan survivin daripada sel-sel 
eksfoliatif serviks tidak boleh digunakan sebagai ujian diagnostik bagi proses malignan serviks. 
 
Kata kunci: Imunoperoksidas tidak langsung; kanser pangkal rahim; survivin; ujian diagnostik; ujian Papanicolaou
INTRODUCTION
Morbidity and mortality rates in women worldwide 
are predominantly caused by cervical cancer. In many 
developed countries, cervical cancer incidence has been 
successfully decreased by the routine Papanicolaou test 
examination. However, this achievement has not appeared 
yet in Indonesia, one of developing countries, owing to 
many reasons (Tjindarbumi et al. 2002). Papanicolaou test 
has some limitations. These limitations due to inadequacy 
of specimen (Cannistra et al. 1996) low sensitivity, and 
high false-negative rate (Williams et al. 1998). However, 
this test is still the most cost-effective test in screening of 
cervical malignancy process (Chen et al. 2003). A better 
technique is needed to identify the true cervical malignancy 
process. Early detection of true cervical malignancy 
process is needed. This cancer can be treated easily in the 
early stage of the disease (Williams et al. 1998). 
 Cancer molecular markers attracted researchers 
attention. For cervical cancer, a good marker is a marker 
that overexpressed in all cervical cancer cases, majority 
of high-grade squamous intraepithelial lesion (HSIL) and 
small percentage of low-grade squamous intraepithelial 
lesion (LSIL) that will progress to cervical cancer (Chen 
et al. 2003). A candidate of cancer molecular marker is 
survivin. Survivin is a member of inhibitory of apoptosis 
protein (IAP) family. It has some activities such as regulator 
of cell cycle, cell proliferation and inhibition of apoptosis. 
It is overexpressed in embryonic, development, and many 
cancer tissues, but undetectable in normally differentiated 
adult tissues (Li, 2005). Overexpression of survivin has been 
linked to radiotherapy resistence (Lu et al. 2004), biomarker 
for aggressive tumor behavior before the appearance of 
tissue abnormalities (Salz et al. 2005), and higher risk for 
local tumor recurrence (Rodel et al. 2005). 
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 Two previous studies evaluated the usefulness of 
survivin overexpression as a marker of cervical cancer (; 
Branca et al. 2005; Frost et al. 2002). In the present study, 
we reexamined the correlation between the Papanicolaou 
test and survivin immunoreactivity of the uterine cervical 
exfoliative cells to confirm the usefulness of survivin 
as a molecular marker of the early stage of the cervical 
carcinoma.
METHODS
PATIENTS AND SAMPLES
Cervical smears were collected from outpatients 
visiting cytology and oncology clinics of Obstetrics and 
Gynecologic Department, Cipto Mangunkusumo Hospital 
in Jakarta, Indonesia between November 19, 2007 and 
February 28, 2008. Every patient was scrapped twice 
in her cervix in order to obtain two samples: one for 
conventional Papanicolaou test and the other for survivin 
expression test. Ethical clearance for the collection of 
cervical smears was provided by The Committee of the 
Medical Research Ethics of the Faculty of Medicine, 
University of Indonesia.
IMMUNOCyTOCHEMISTRy
Cervical smears were fixed in absolute ethanol and acetic 
acid (95:5) for 15 min on silane-coated slides. Smears were 
incubated with a solution of 3.0% H2O2 in absolute methanol 
for 30 min. Non-specific staining was blocked using normal 
goat serum (G9023, Sigma) for 10 min. The slides were 
incubated overnight at 4oC with a specific polyclonal 
primary antibody (antisurvivin antibody produced in rabbit, 
S8191, Sigma), at 1:100 dilution. This antibody detects 
human survivin by immunoblotting (16 kDa). The samples 
were then rinsed in phosphate-buffered saline (PBS) and 
incubated for 30 min with secondary antibody (antirabbit 
antibody-peroxidase conjugated produced in rabbit, 
A9169, Sigma) at 1:100 dilution. Finally, the samples 
were developed with diaminobenzidine tetrahydrochloride 
substrate (SigmaFast™ DAB, D4293, Sigma) for 5 min, 
slightly counterstained with hematoxylin, dehydrated and 
mounted with Entellan™.
 The validation of the use of the antibody against 
survivin for immunocytochemistry was carried out in 
24 h with absolute ethanol and acetic acid (95:5)-fixed 
testes of Sprague Dawley rat. Testes was dehydrated by 
graded alcohol, cleared in xylol and embedded in paraffin. 
The paraffinized testes tissue block was sectioned 5 μm 
thin and the sections were mounted on silane-coated 
slides. After deparaffinization process, the sections were 
rehydrated and incubated with a solution of 3.0% H2O2 
in absolute methanol for 30 min. Non-specific staining 
was blocked using normal goat serum (G9023, Sigma) 
for 10 min. A section was incubated overnight at 4oC 
with a specific polyclonal primary antibody (antisurvivin 
antibody produced in rabbit, S8191, Sigma), at 1:100 
dilution. The omission of the primary antibody on 
another incubated section was used as negative control. 
Sections were then rinsed in phosphate-buffered saline 
(PBS) and incubated for 30 min with secondary antibody 
(antirabbit antibody-peroxidase conjugated produced in 
rabbit, A9169, Sigma) at 1:100 dilution. Sections were 
developed with diaminobenzidine tetrahydrochloride 
substrate (SigmaFast™ DAB, D4293, Sigma) for 5 min, 
slightly counterstained with hematoxylin, dehydrated and 
mounted with Entellan™. 
STATISTICAL ANALySIS
Due to ethical issue, we decided to use Papanicolaou 
test result as an indicator for the presence of cervical 
abnormality. Interpretation of the Papanicolaou test was 
based on The 2001 Bethesda System. The cancer, high-
grade squamous intraepithelial lesion (HSIL), low-grade 
squamous intraepithelial lesion (LSIL), and atypical lesion 
were then classified as positive for the presence of disease. 
Normal Papanicolaou test result was classified as negative 
for the presence of disease.
 The percentage of immunoreactive cells was assessed 
on all samples. Positive samples were determined and 
analyzed as proposed previously. Positive samples were 
analyzed semi-quantitatively in at least twenty five areas 
at x450 magnification. Cases were scored positive when 
>5% of the cells reacted with the anti-survivin antibody. 
Assessment of all staining was blinded to knowledge of 
the Papanicolaou test result.
 Correlation of survivin expression of positive cases 
with the presence of disease based on Papanicolaou test 
results was calculated using Fischer’s-exact test. P value 
≤0.05 was considered to indicate statistical significance. 
RESULTS
VALIDATION IN SPRAGUE DAWLEy RAT TESTES
Survivin was overexpressed in the testes of Sprague 
Dawley rat. Immunolocalization of survivin in rat testes 
is in cytoplasm. No immunoreactivity was identified in the 
control (no primary antibody) section (Figure 1). 
SURVIVIN ExPRESSION IN CERVICAL ExFOLIATIVE CELLS
Survivin is expressed in parabasal cells, intermediate cells 
and metaplastic cells (Figure 2). Survivin expression can be 
found both in cytoplasm and nucleus or only in cytoplasm. 
Survivin expression is found in many, but not all, samples 
with normal and intraepithelial lesions in Papanicolaou test 
results (Table 1). The same results were found in samples 
from post-therapeutic cancer samples. We did not find any 
samples with cancer lesion for survivin expression test.
 Table 1 shows the positive cases of survivin expression 
related to the presence or absence of the cervical 
abnormality detected by the Papanicolaou test. Positive 
cases were found in 13 of 90 women.
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FIGURE 1. Positive and negative control of survivin expression in rat testes. 
Inset: negative control 
FIGURE 2. Survivin expression in cervical exfoliative cells. No immunoreactivity is identified in the control smear (photograph (a)). 
Photograph (b), (c) and (d) show survivin-immunopositive cells. Bars in (a)-(d) = 20 um
(a) (b)
(d)(c)
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 Fischer’s-exact test showed that immunocytochemistry 
of survivin expression was not significant as cancer 
molecular marker (1-sided, p = 0.553; 2-sided, p = 1). 
The performance indicators are: sensitivity = 30.76%, 
specificity = 71.42%, PPV = 15.38%, and NPV = 85.93%. 
DISCUSSION
World Health Organization recommended that a good 
diagnostic test is a test with specificity of 98-99% (WHO 
2002). Diagnostic test in a country with low prevalence 
should be directed to increasing specificity. However, 
diagnostic test in a country with high prevalence should 
be directed to increase sensitivity (Pusponegoro et al. 
2006). 
 Survivin has been studied in many cancers such as 
lung (Nakanishi et al. 2003), colon (Ashanuma et al. 
2004) and cervix (Branca et al. 2005; Frost et al. 2002; 
Li 2003). Therefore, survivin is not a tissue specific of 
cancer molecular marker. However, The Prognostic Factor 
Committee of the European Society of Gynecological 
Oncology has concluded that there is an urgent need for 
specific prognostic biomarkers in cervical carcinoma (Frost 
et al. 2002). 
 Many molecules have been proposed as biomarker. 
Using microarray, Carlsson studied 140 genes that 
represent many biomarkers. Keratin 19 increases 21.2 
fold (Carlson 2006). However Maddox et al. (1999) 
using immunohistochemistry, showed that keratin 19 
expression was not significantly different in invasive 
cervical carcinoma, cervical intraepithelial neoplasia (CIN), 
metaplasia, and normal epithelium. Using northern blot 
analysis it was found that in many cases, survivin mRNA 
level has increased 2 fold compared to normal cervix tissue 
(Maddox et al. 1999). The result of this present study has 
similarity with Maddox et al. (1999)study. However, high 
false negative rate of Papanicolaou test is still needed to be 
considered as a factor that influenced the result. Another 
factor is, may be, the low sensitivity of immunostaining 
compared to microarray test.
 Frost et al. (2002) showed that there is a staining 
pattern of survivin expression in normal benign squamous 
mucosa, cervical dysplasia, and invasive squamous 
carcinoma. However, Branca et al. (2005) reported that 
survivin expression is not found in normal or metaplastic 
squamous epithelium. This study is consistent with Frost 
et al. (2002) study. Metaplastic cells that show survivin 
expression are found in normal and abnormal Papanicolaou 
test samples. Survivin expression is regulated by many 
factors and survivin gene promoter domain. Human 
papilloma virus (HPV)-infected cervical cells will results 
in degradation of p53 and releasing of E2F-1. These 
results can interfere with survivin gene promoter domains 
resulting in overexpression of survivin. Therefore, we 
suggest that overexpression of survivin can be found in 
the HPV infected cervical cells.
 Many cervical tumors are in infected forms and 
partially necrotic (Geisler et al. 2001). Chemotherapy 
and radiotherapy kill cancer cells by inducing apoptosis. 
In the lung squamous carcinoma, there is no significant 
correlation between chemotherapy response and survivin 
expression or localization. There is no correlation therapy 
modality and chemotherapy (Vischioni et al. 2004). These 
features may explain why survivin expression is not highly 
expressed in post-therapeutic cancer exfoliative cells.
CONCLUSION
Although it is difficult to decide whether survivin 
expression is an early sign of abnormal change toward 
cancer or related to normal cell cycle, the present study 
revealed that survivin is not suitable for the molecular 
marker of the cervical cancer. We need a prospective study 
to examine survivin expression role as a cancer molecular 
marker that appears early in malignancy process. 
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